Ariel Feldstein
Overview
Explore the profile of Ariel Feldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leszczynska A, Stoess C, Sung H, Povero D, Eguchi A, Feldstein A
Biomedicines
. 2023 Oct;
11(10).
PMID: 37893181
Chronic liver diseases can lead to fibrotic changes that may progress to the development of cirrhosis, which poses a significant risk for morbidity and increased mortality rates. Metabolic dysfunction-associated steatotic...
2.
Patel N, Peterson M, Lin G, Feldstein A, Schnabl B, Bettencourt R, et al.
Gastroenterol Res Pract
. 2013 Dec;
2013:498296.
PMID: 24348536
Background. Ectopic fat deposition in the pancreas and its relationship with hepatic steatosis and insulin resistance have not been compared between patients with nonalcoholic fatty liver disease (NAFLD) and healthy...
3.
Bansal S, Berk M, Alkhouri N, Partrick D, Fung J, Feldstein A
J Surg Res
. 2013 Oct;
186(1):29-38.
PMID: 24135379
Background: Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, when it is not amenable for aggressive therapies such as surgical resection or liver transplantation. Current therapeutic options achieve...
4.
Moses J, Alkhouri N, Shannon A, Feldstein A, Carter-Kent C
Inflamm Bowel Dis
. 2011 Sep;
17(12):E160.
PMID: 21953938
No abstract available.
5.
Nobili V, Della Corte C, Monti L, Alisi A, Feldstein A
Ital J Pediatr
. 2011 Aug;
37:36.
PMID: 21810223
Non-alcoholic fatty liver disease (NAFLD) has become over the last decade the most common form of chronic liver disease in children and adults. Thus, establishing the diagnosis of NAFLD is...
6.
Feldstein A, Kleiner D, Kravetz D, Buck M
J Clin Gastroenterol
. 2008 Dec;
43(4):374-81.
PMID: 19098685
Goals: To describe the mechanisms of severe hepatocellular injury with apoptosis in 2 patients receiving hepatitis C virus (HCV)-796. Background: HCV-796 is a hepatitis C polymerase inhibitor approved by the...
7.
Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A, et al.
Gastroenterology
. 2005 Jul;
129(1):113-21.
PMID: 16012941
Background & Aims: The natural history of nonalcoholic fatty liver disease (NAFLD) in the community remains unknown. We sought to determine survival and liver-related morbidity among community-based NAFLD patients. Methods:...
8.
Feldstein A, Gores G
Am J Gastroenterol
. 2004 Aug;
99(9):1718-9.
PMID: 15330908
No abstract available.
9.
Adams L, Feldstein A, Lindor K, Angulo P
Hepatology
. 2004 Apr;
39(4):909-14.
PMID: 15057893
Patients with hypopituitarism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought...
10.
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse
Canbay A, Feldstein A, Baskin-Bey E, Bronk S, Gores G
J Pharmacol Exp Ther
. 2003 Nov;
308(3):1191-6.
PMID: 14617689
Liver injury is characterized by hepatocyte apoptosis and collagen-producing activated hepatic stellate cells (HSC). Hepatocyte apoptosis promotes liver injury and fibrosis, whereas activated HSC apoptosis limits hepatic fibrosis. Pharmacological inhibition...